论文部分内容阅读
体内和体外实验均证明胶质细胞源性的神经营养因子(glial cell line-derived neurotrophicfactor,GDNF)对多巴胺(DA)能神经元有较好的保护作用,为治疗帕金森氏病提供了启示.但这些证据均来自应用GDNF蛋白进行的实验,而GDNF蛋白不能通过血脑屏障,不利于临床应用,若能把携带GDNF基因的工程细胞移植入脑内,使其稳定高效地表达,则对帕金森氏病的防治将有积极意义.本研究把携带GDNF cDNA的重组质粒转入NIH 3T3细胞系,筛出稳定表达的克隆,与SD大鼠原代多巴胺能神经元共培养,观察到明显的保护作用,为用Ex Vivo法治疗帕金森氏病奠定了基础.
Both in vivo and in vitro experiments demonstrated that glial cell line-derived neurotrophic factor (GDNF) has a good protective effect on dopaminergic neurons and provides an indication for the treatment of Parkinson’s disease. However, all of these evidences come from experiments using GDNF protein. However, GDNF protein can not cross the blood-brain barrier and is not conducive to clinical application. If the engineering cells carrying the GDNF gene can be implanted into the brain stably and efficiently, The prevention and treatment of Parkinson’s disease will be of positive significance.In this study, the recombinant plasmid carrying GDNF cDNA was transferred into NIH 3T3 cell line, and the stable clone was screened and co-cultured with primary rat dopaminergic neurons of SD rats. The protective effect laid the foundation for the treatment of Parkinson’s disease with Ex Vivo.